Cargando…
P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621529/ http://dx.doi.org/10.1097/01.HS9.0000890948.68238.c6 |
| _version_ | 1784821578019635200 |
|---|---|
| author | Jones, David Shakir, Rebecca Candio, Paolo Ramroth, Johanna Wolstenholme, Jane Gray, Alastair Cutter, David Ntentas, Georgios |
| author_facet | Jones, David Shakir, Rebecca Candio, Paolo Ramroth, Johanna Wolstenholme, Jane Gray, Alastair Cutter, David Ntentas, Georgios |
| author_sort | Jones, David |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621529 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96215292022-11-01 P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England Jones, David Shakir, Rebecca Candio, Paolo Ramroth, Johanna Wolstenholme, Jane Gray, Alastair Cutter, David Ntentas, Georgios Hemasphere Radiotherapy Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621529/ http://dx.doi.org/10.1097/01.HS9.0000890948.68238.c6 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Radiotherapy Jones, David Shakir, Rebecca Candio, Paolo Ramroth, Johanna Wolstenholme, Jane Gray, Alastair Cutter, David Ntentas, Georgios P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England |
| title | P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England |
| title_full | P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England |
| title_fullStr | P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England |
| title_full_unstemmed | P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England |
| title_short | P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England |
| title_sort | p095: personalised modelling of quality-adjusted survival benefit and cost-effectiveness of using proton beam therapy inthe treatment of intermediate-stage hodgkin lymphoma in england |
| topic | Radiotherapy |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621529/ http://dx.doi.org/10.1097/01.HS9.0000890948.68238.c6 |
| work_keys_str_mv | AT jonesdavid p095personalisedmodellingofqualityadjustedsurvivalbenefitandcosteffectivenessofusingprotonbeamtherapyinthetreatmentofintermediatestagehodgkinlymphomainengland AT shakirrebecca p095personalisedmodellingofqualityadjustedsurvivalbenefitandcosteffectivenessofusingprotonbeamtherapyinthetreatmentofintermediatestagehodgkinlymphomainengland AT candiopaolo p095personalisedmodellingofqualityadjustedsurvivalbenefitandcosteffectivenessofusingprotonbeamtherapyinthetreatmentofintermediatestagehodgkinlymphomainengland AT ramrothjohanna p095personalisedmodellingofqualityadjustedsurvivalbenefitandcosteffectivenessofusingprotonbeamtherapyinthetreatmentofintermediatestagehodgkinlymphomainengland AT wolstenholmejane p095personalisedmodellingofqualityadjustedsurvivalbenefitandcosteffectivenessofusingprotonbeamtherapyinthetreatmentofintermediatestagehodgkinlymphomainengland AT grayalastair p095personalisedmodellingofqualityadjustedsurvivalbenefitandcosteffectivenessofusingprotonbeamtherapyinthetreatmentofintermediatestagehodgkinlymphomainengland AT cutterdavid p095personalisedmodellingofqualityadjustedsurvivalbenefitandcosteffectivenessofusingprotonbeamtherapyinthetreatmentofintermediatestagehodgkinlymphomainengland AT ntentasgeorgios p095personalisedmodellingofqualityadjustedsurvivalbenefitandcosteffectivenessofusingprotonbeamtherapyinthetreatmentofintermediatestagehodgkinlymphomainengland |